For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH6174Ka&default-theme=true
RNS Number : 6174K Medpal AI PLC 08 December 2025
8 December 2025
MedPal AI plc
("MedPal AI" or the "Company")
Major App Update and Rollout to Epassi UK Gym Network
MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on health and wellness management, is pleased to
announce the release of a major upgrade to its MedPal AI wellness app on both
iOS and Android platforms.
Major App Enhancement
The Company has released a significant update to its MedPal AI app (available
at iOS App Store (https://apps.apple.com/us/app/medpal-ai/id6740333362) or
Google Play Store
(https://play.google.com/store/apps/details?id=com.medpal.ai.med_pal) ),
introducing advanced AI capabilities that represent a substantial evolution in
its personalised health management.
The new unified AI assistant allows users to interact via text, voice, or
image within a single chat interface covering wellness, fitness, sleep,
recovery, and nutrition. The redesigned dashboard features faster loading,
updated health metric formulas, and real-time data sync with six-month
historical import. An enhanced journal feature now supports AI-powered
analysis of uploaded documents and lab results. The update also introduces
German language support. Key features include;
· Test Results Upload: Users can now upload test results
directly into the app, enabling the AI to provide more comprehensive and
contextualised health insights;
· Portable Health Records: Wherever you are, you will have
all of your test results and documents stored with you on your MedPal app;
· AI Memory Function: The app now builds a continuous
memory of each user's health journey, enabling increasingly personalised
recommendations based on historical patterns and trends; and
· Enhanced Personalisation: The AI system learns from user
data over time, delivering wellness guidance that becomes increasingly
accurate and tailored to individual needs.
This update significantly enhances the app's value proposition by transforming
it from a real-time health data aggregator into an intelligent, longitudinal
health companion that monitors each user's unique health trajectory.
Epassi Partnership Deployment
The updated app is now being rolled out across networks of UK gyms under the
Company's partnership agreement with Epassi UK Limited. This partnership
provides access to 11 million+ employees at major firms including Siemens and
Volvo, representing a significant distribution channel for the enhanced app
capabilities.
The timing of this major release with the Epassi rollout positions MedPal AI
to capture substantial user engagement across the corporate wellness sector,
offering free 12-month access to Epassi's 11 million+ users as part of
employee wellness benefits. Subscription options for premium features are
available at £3.99 monthly or £29.99 annually.
Jason Drummond, Chief Executive Officer of MedPal AI, commented:
"This major app update represents a significant leap forward in our AI
capabilities. The ability to upload test results and have our AI build a
comprehensive memory of each user's health profile creates a truly
personalised wellness experience that goes beyond simple activity tracking.
"The rollout to UK gyms through our Epassi partnership provides immediate
access to millions of potential users who will benefit from these advanced
features. This positions MedPal AI at the forefront of AI-powered preventive
healthcare, combining our existing strength in wearable data aggregation with
deeper insights from test results and longitudinal health patterns.
"We continue to enhance our dual-engine model, where our wellness app drives
user engagement and awareness, whilst MedPal.clinic provides the pharmacy and
clinical fulfilment. This latest update strengthens that flywheel
significantly."
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer Via Square1 Consulting
Cairn Financial Advisers LLP +44 (0) 20 7213 0880
Louise O'Driscoll/Jo Turner
Clear Capital Markets Limited +44 (0) 20 3869 6080
Bob Roberts/ Nick Josh
Square1 Consulting +44 (0) 20 7929 5599
David Bick +44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDTRBMTMTTMTIA
Copyright 2019 Regulatory News Service, all rights reserved